Orion Oyj B
FIEUROrion Oyj B (LSE:0M2O) — Drug Manufacturers - General. Antal børser, hvor selskabets aktier handles: 3. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- orionpharma.com
- Sektor
- Healthcare · Drug Manufacturers - General
- Hovedkontor
- Espo, Finland
- Administrerende Direktør
- Liisa Hurme
- Ansatte
- 4 000
- Børsnoteret Siden
- 07.11.2007 (LSE:0M2O)
- Udestående Aktier
- 108.99 mio.
- Free Float
- 123.49 mio.
- Markedsværdi
- 11.42 mia. EUR
- Insidere
- 2.63%
- Institutionelle Investorer
- 45.48%
- Udbetalingsgrad
- 41.3%
- FCF
- 380 mio. EUR
- Udbetaling / FCF
- 64%
- Gæld
- 133 mio. EUR0.3 år FCF
- Udbyttestreak
- 21 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
Beskrivelse
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
Udbytte
Orion Oyj B (ORINF) udbetaler udbytte to gange om året. Pr. År (12 måneder op til og med den senest annoncerede betaling): 1.8 EUR pr. Aktie (betalinger: 1). Den næste ex-udbyttedato er 20.10.2026: 0.9 EUR pr. Aktie, betalt den 27.10.2026. Uafbrudt udbyttehistorik: 21 år.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-10-20 annonceret | 2026-10-27 | 0.9000 EUR | 1.1/2.2 % | halvårlig | US:ORINF |
| 2026-03-25 | 2026-04-02 | 0.9000 EUR | 1.3/2.6 % | halvårlig | HE:ORNBV |
| 2025-10-15 | 2025-10-23 | 0.8200 EUR | 1.2/2.4 % | halvårlig | HE:ORNBV |
| 2025-04-04 | 2025-04-14 | 0.8200 EUR | 1.5/2.9 % | halvårlig | HE:ORNBV |
| 2024-10-15 | 2024-10-23 | 0.8100 EUR | 1.7/3.4 % | halvårlig | HE:ORNBV |
| 2024-03-21 | 2024-04-03 | 0.8100 EUR | 2.3/2.3 % | årlig | HE:ORNBV |
| 2023-03-23 | — | 1.6000 EUR | 3.7/3.7 % | årlig | HE:ORNBV |
| 2022-03-24 | — | 1.5000 EUR | 3.5/3.5 % | årlig | HE:ORNBV |
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| BlackRock, Inc. | ≈6.43% | 7.07 mio. | 2025-04-24 |
| VANGUARD STAR FUNDS-Vang… | 1.42% | 1.56 mio. | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.95% | 1.04 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.75% | 825 344 | 2026-08-31 |
| DFA INVESTMENT TRUST CO-… | 0.55% | 600 779 | 2026-07-31 |
| DFA INVESTMENT DIMENSION… | 0.45% | 497 917 | 2026-07-31 |
| Fidelity Concord Street… | 0.39% | 426 245 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.35% | 379 664 | 2026-08-31 |
| SPDR-EUROPE-SSgA SPDR ET… | 0.34% | 374 245 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.23% | 254 097 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.23% | 253 858 | 2026-07-31 |
| Pacer Advisors, Inc. | 0% | 485 | 2026-06-30 |
